Long-term outcomes of early stent thrombosis after implanting new-generation drug-eluting stents

Prognosis of early stent thrombosis of new-generation drug-eluting stents in a contemporary setting

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN14411820

Enrollment

300

Registered

2022-11-09

Start date

2023-01-01

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early stent thrombosis Circulatory System

Interventions

Eligible patients who were admitted at the centers between January 1st 2016 and January 1st 2022 were recruited. The following brief protocol was conducted using telephone interviews:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who suffered from definite early stent thrombosis (EST) (defined as angiographically confirmed ST) after the index percutaneous coronary intervention with new-generation drug-eluting stent

Exclusion criteria

Exclusion criteria: 1. Patients who encounter late stent thrombosis (LST) and very late stent thrombosis (VLST) 2. Patients who experience probable stent thrombosis (ST; defined as any unexplained death within 30 days of percutaneous coronary intervention or any myocardial infarction that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause) or possible ST ( defined as any unexplained death from 30 days after intracoronary stenting until end of trial follow-up) 3. Patients with ST that occurs in a vein graft culprit 4. Patients treated with bare-metal stents (BMS) and/or first-generation DES at the index procedure

Design outcomes

Primary

Measure	Time frame
Major adverse cardiovascular events (MACE) measured using telephone interviews with the patients or their family members, and by interrogating hospital or outpatient clinic records at five years follow-up	—

Secondary

Measure	Time frame
1. Cardiac death measured using telephone interviews with the patients or their family members, and by interrogating hospital or outpatient clinic records at five years follow-up 2. Recurrent definite stent thrombosis measured using telephone interviews with the patients or their family members, and by interrogating hospital or outpatient clinic records at five years follow-up 3. Stroke measured using telephone interviews with the patients or their family members, and by interrogating hospital or outpatient clinic records at five years follow-up	—

Measure

Time frame

1. Cardiac death measured using telephone interviews with the patients or their family members, and by interrogating hospital or outpatient clinic records at five years follow-up 2. Recurrent definite stent thrombosis measured using telephone interviews with the patients or their family members, and by interrogating hospital or outpatient clinic records at five years follow-up 3. Stroke measured using telephone interviews with the patients or their family members, and by interrogating hospital or outpatient clinic records at five years follow-up

—

Countries

China

Contacts

Public ContactLe-Feng Wang

wanglefeng@mail.ccmu.edu.cn+86 (010) 85231170

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026